Related Experiment Video
Updated: Jun 20, 2025

08:49
Models of Bone Metastasis
Published on: September 4, 2012
42.1K
Supportive care interventions in metastatic bone disease: scoping review
Samuel K Simister1, Rahul Bhale1, Amy M Cizik2
1Department of Orthopaedics, University of California Davis, Sacramento, California, USA.
BMJ Supportive & Palliative Care
|July 22, 2024
Summary
Supportive care interventions for metastatic bone disease (MBD) are feasible and measurable. Further research is needed to reduce fracture risk and improve quality of life for MBD patients.
Area of Science:
- Oncology
- Palliative Care
- Clinical Trials Research
Background:
- Metastatic bone disease (MBD) significantly impacts cancer patient quality of life.
- Growing population of patients with secondary musculoskeletal involvement from primary cancers.
- Lack of rigorous reviews on supportive care interventions for MBD.
Purpose of the Study:
- To review and appraise clinical trials on supportive care interventions for MBD.
- To examine intervention characteristics, study designs, and evidence quality.
Main Methods:
- Searched PubMed, CINAHL, and Google Scholar (Sept 2017-2022).
- Included clinical trials, systematic reviews, and meta-analyses.
- Evaluated evidence quality based on treatment types and study design.
Main Results:
- 13 articles (7 trials, 2 protocols, 4 reviews) were included from 572 publications.
- Feasible interventions: palliative care, radiotherapy, alternative medicines.
- Interventions focused on fatigue and pain; no fracture-specific endpoints reported.
Conclusions:
- Supportive care for MBD is feasible and measurable using patient-reported outcomes.
- Evidence quality is moderate to strong, but few trials address skeletal events.
- Further trials needed for fracture risk reduction and quality of life improvement.
More Related Videos
Related Concept Videos
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K

